How has been the historical performance of Nexus Surgical?

Answer:The historical performance of Nexus Surgical shows a significant upward trend in net sales, with figures rising from 1.55 Cr in Mar'23 to 5.72 Cr in Mar'25. Total operating income followed a similar trajectory, increasing from 1.55 Cr in Mar'23 to 5.72 Cr in Mar'25. The company's total expenditure also rose, from 1.34 Cr in Mar'23 to 5.06 Cr in Mar'25, but the operating profit (PBDIT) improved from 0.21 Cr in Mar'23 to 0.67 Cr in Mar'25, indicating better cost management relative to sales growth. Profit before tax and profit after tax also saw positive growth, with profit before tax increasing from 0.23 Cr in Mar'23 to 0.67 Cr in Mar'25, and profit after tax rising from 0.17 Cr to 0.50 Cr in the same period. The earnings per share (EPS) improved significantly from 0.31 in Mar'23 to 0.91 in Mar'25, reflecting enhanced profitability. The company's total assets increased from 0.91 Cr in Mar'23 to 2.27 Cr in Mar'25, while total liabilities rose from 0.91 Cr to 2.27 Cr, indicating a balanced growth in both assets and liabilities.

Breakdown:
Nexus Surgical's financial performance has shown a robust growth pattern over the years. The net sales surged from 1.55 Cr in Mar'23 to 5.72 Cr in Mar'25, reflecting a strong demand for its products. This growth in sales translated into total operating income, which matched the sales figures. Despite an increase in total expenditure from 1.34 Cr to 5.06 Cr, the company managed to enhance its operating profit from 0.21 Cr to 0.67 Cr, indicating improved efficiency. The profit before tax and profit after tax also demonstrated positive trends, with both metrics showing substantial increases, highlighting the company's ability to convert sales into profit effectively. The earnings per share rose significantly, indicating better returns for shareholders. Furthermore, total assets and total liabilities grew in tandem, suggesting that Nexus Surgical is expanding its operations while maintaining a balanced financial structure.